Dr. Kopetz on the Rationale for the BEACON CRC Study in BRAF V600E-Mutant mCRC

preview_player
Показать описание
Scott Kopetz, MD, PhD, FACP, discusses the rationale for the phase 3 BEACON CRC trial in BRAF V600E-mutant metastatic colorectal cancer.

Рекомендации по теме